Tumor‐Adhesive Chitosan‐Derived Multi‐Immune Agonist Unleashes Strong and Durable Anti‐Cancer Immunity
Advanced Science · 2025
DOI: 10.1002/advs.202414110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Huilan He und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123, China. Hauptthemen laut MEDLINE: Chitosan, Immunotherapy, Tumor Microenvironment, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Natural Science Foundation of the Jiangsu Higher Education Institutions of China.
Abstract (Originalsprache)
The immunomodulation of the tumor microenvironment is critical for effective cancer immunotherapy, particularly for tumors that exhibit limited responses to conventional treatments. However, current immune agonists developed for tumor immunomodulation face several challenges, such as poor intratumoral retention, inadequate biocompatibility, and restricted cellular targets, which ultimately hamper their therapeutic efficacy and clinical application. In this study, a tumor‐adhesive chitosan‐tethered immune agonist construct (TACTIC) is introduced, which demonstrates good biocompatibility and robust immunostimulatory effects, enhancing the immunogenicity of tumor cells while simultaneously stimulating pro‐inflammatory responses in various immune cell populations. Mechanistic investigations reveal that TACTIC targets multiple signaling pathways, conferring it to effectively remodel the irradiated tumor microenvironment, improve tumor control on murine cancer models post‐radiotherapy, and elicit systemic immune responses with memory effects. The findings highlight the potential of TACTIC as a powerful macromolecular immune adjuvant, paving the way for its broader application in innovative cancer immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmaceutical Sciences and State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, 215123, China.
- Biomedical Polymers Laboratory, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou, 215123, China.
- School of Optical and Electronic Information, Suzhou City University, Suzhou, 215104, China.
ORCID-Profile: Zhiyuan Zhong
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Natural Science Foundation of the Jiangsu Higher Education Institutions of China
Zitieren
APA
He, H., Liu, L., Zheng, Y., Ji, J., Cao, L., Ye, C., Sun, Y., Zhang, Y., & Zhong, Z. (2025). Tumor‐Adhesive Chitosan‐Derived Multi‐Immune Agonist Unleashes Strong and Durable Anti‐Cancer Immunity. Advanced Science. https://doi.org/10.1002/advs.202414110
Vancouver
He H, Liu L, Zheng Y, Ji J, Cao L, Ye C, et al. Tumor‐Adhesive Chitosan‐Derived Multi‐Immune Agonist Unleashes Strong and Durable Anti‐Cancer Immunity. Advanced Science. 2025. doi:10.1002/advs.202414110
BibTeX
@article{He2025,
author = {He, Huilan and Liu, Liang and Zheng, Yun and Ji, Jinlong and Cao, Li and Ye, Chunlian and Sun, Yu and Zhang, Ying and Zhong, Zhiyuan},
title = {Tumor‐Adhesive Chitosan‐Derived Multi‐Immune Agonist Unleashes Strong and Durable Anti‐Cancer Immunity},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202414110}
}
EUVIMED